Oklahoma-UT Southwestern Hemostasis Consortium

俄克拉荷马州-犹他州西南止血联盟

• 批准号: 8470372
• 负责人: JAMES N GEORGE
• 金额: $ 7.97万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8470372
• 关键词: Childhood; Clinical Trials; Decision Analysis; Development; Devices; Enrollment; Faculty; Frequencies; Hemophilia A; Hemostatic function; Heparin; Infection; Lead; Oklahoma; Outcome; Participant; Patients; Protocols documentation; Research; Research Personnel; Role; Site; Subgroup; Thromboembolism; Universities; Venous; Work; interest; member; mimetics; programs; protocol development

DESCRIPTION (provided by applicant) The Oklahoma-UT Southwestern Hemostasis Consortium has been an active participant of the TMH CTN for the first four years of the network activity. Investigators from our consortium have had leading roles in the subgroups devoted to TIP, IIP, hemophilia, pediatric and HIT protocol development. In addition, both sites of our consortium have very effectively enrolled patients in the initial network .clinical trial, PLADO. For TTP, Dr. George was the initial co-chair of this subcommittee and remains a leader in the development of the STAR trial. His colleagues at Oklahoma, Dr. Sara Vesely and Ms. Dee Terrell, have also contributed in key roles to the STAR trial development: Dr. Vesely with biostatistical analysis and Ms. Terrell as one of the two key clinical trial coordinators developing this study. Both Drs. George and Buchanan have been leaders in the ITP subcommittee, working to develop a protocol for childhood ITP using a TPO-mimetic agent. Dr. Buchanan was the initial leader of the pediatric subcommittee, and has contributed to the development of a decision analysis protocol to determine the critical research questions for childhood ITP. Dr. Buchanan and two of our beginning faculty, Dr. Janna Journeycake at UT Southwestern and Dr. Kapil Saxena of Oklahoma have been key contributors to the development of the RICH study. When this study opens we anticipate being one of the leading sites for the clinical trial. Drs. Buchanan and Journeycake have also been very active in the development of the study to evaluate the role of rTPA in reducing central venous access device infection in patients with hemophilia. This has been a major research interest of Drs. Journeycake and Buchanan. Dr. Ravi Sarode of UT Southwestern has been a leader in the development of the protocol to determine the frequency of thromboembolism related to heparin, the HOT study, and he anticipates being the lead enrolling center for this study. The TMH CTN has brought our two university centers closer together with many collaborative interactions. A valuable outcome of the past four years has been the extension of collaborative relationship to the junior faculty members and trainees in our programs.

描述（由申请人提供） 俄克拉荷马-UT西南止血联盟在网络活动的前四年一直是TMH CTN的积极参与者。我们联盟的研究者在致力于TIP、IIP、血友病、儿科和HIT方案开发的亚组中发挥了主导作用。此外，我们联盟的两个研究中心都非常有效地招募了最初网络临床试验PLADO的患者。对于TTP，乔治博士是该小组委员会的最初联合主席，并且仍然是星星试验开发的领导者。他在俄克拉荷马州的同事Sara Vesely博士和Dee特雷尔女士也在星星试验开发中发挥了关键作用：Vesely博士负责生物统计分析，特雷尔女士是开发本研究的两名关键临床试验协调员之一。乔治博士和布坎南博士都是ITP小组委员会的领导人，致力于开发一种使用TPO模拟剂治疗儿童ITP的方案。Buchanan博士是儿科小组委员会的最初领导者，并为制定决策分析方案以确定儿童ITP的关键研究问题做出了贡献。布坎南博士和我们的两个开始教师，博士Janna callneycake在UT西南和博士Kapil Saxena的俄克拉荷马州一直是关键贡献者丰富的研究的发展。当这项研究开始时，我们预计将成为临床试验的主要研究中心之一。Buchanan博士和Barneycake博士也非常积极地参与了这项研究的开发，以评价rTPA在减少血友病患者中心静脉输液装置感染中的作用。这一直是Drs. Barneycake和Buchanan的主要研究兴趣。UT西南大学的Ravi Sarode博士一直是HOT研究方案开发的领导者，该方案旨在确定与肝素相关的血栓栓塞频率，他预计将成为本研究的主要招募中心。TMH CTN通过许多合作互动使我们两所大学的中心更加紧密。过去四年的一个有价值的成果是合作关系的延伸，以初级教师和学员在我们的计划。